Cisplatin is one of the commonly used chemotherapeutic drugs for the treatment of head and neck squamous cell carcinoma (HNSCC). However, acquisition of cisplatin resistance is common in patients with HNSCC and it often leads to local and distant failure. In this study, we demonstrate that survivin expression is significantly upregulated in HNSCC primary tumors and cell lines. In addition, survivin levels were significantly higher in HPV negative patients that normally respond poorly to cisplatin treatment. Survivin expression was further increased in cisplatin resistant cells (CAL27-CisR) as compared to its parent cells (CAL27). Therefore, we hypothesize that targeting of survivin in HNSCC could reverse the resistant phenotype in tumor cells thereby enhancing the therapeutic efficacy of cisplatin. We used both in vitro and in vivo models to test the efficacy of YM155, a small molecule survivin inhibitor, either as a single agent or in combination with cisplatin. YM155 significantly decreased survivin levels and cell proliferation in a dose-dependent manner. In addition, YM155 pretreatment significantly reversed cisplatin resistance in cancer cells. Interestingly, YM155 treatment altered the dynamic localization of survivin in cells by inducing a rapid reduction in cytoplasmic survivin, which plays a critical role in its anti-apoptotic function. In a SCID mouse xenograft model, YM155 significantly enhanced the anti-tumor and anti-angiogenic effects of cisplatin with no added systemic toxicity. Taken together, our results suggest a potentially novel strategy to use YM155 to overcome the resistance in tumor cells thereby enhancing the effectiveness of the chemotherapy in HNSCC.
INTRODUCTION
Head and neck cancer is the sixth leading cancer by incidence worldwide and approximately 600,000 cases are diagnosed worldwide every year. In the United States, an estimated 40,250 new cases of head and neck cancer were expected in 2012 (1) . Although advancements in the techniques for surgery, radiation and chemotherapy have increased the local control of HNSCC, the overall survival rates have not improved significantly over the last three decades. This poor outcome becomes even worse (20% 5-year survival rate) for advanced stage HNSCC patients whose tumors are not amenable for surgery (2) . Cisplatin is one of the most commonly used chemotherapeutic agents used for the treatment of head and neck cancers (3).
However, many patients acquire resistance to chemotherapeutic agents leading to treatment failures. Prognosis of such patients who have to undergo late salvage surgery is very poor (4) . Therefore, it is important to understand the molecular mechanisms that contribute to drug resistance in order to identify novel therapeutic targets for head and neck cancer.
One such protein that has been identified to be deregulated in a number of human tumors is survivin. It is a bifunctional protein that acts as a suppressor of apoptosis and has an essential role in mitosis (5) . It is a nuclear and cytoplasmic shuttling protein that is predominantly cytoplasmic in part because of an active nuclear export signal (NES) in its linker region (6) .
Cytoplasmic survivin predominantly mediates the anti-apoptotic function; whereas nuclear survivin mediates the mitotic function and is significantly less stable (6) (7) (8) . Survivin is largely undetected or expressed at very low levels in normal tissues (9) , whereas it is overexpressed in many malignancies including breast, lung, colon, pancreas, liver and head and neck cancer and has also been linked to poor patient survival (10, 11) . In addition, growing evidence suggest that survivin expression is associated with drug-resistance in cancer cells and cancer associated 4 endothelial cells (12) (13) (14) (15) (16) (17) . Therefore, we hypothesize that targeting of survivin in head and neck cancer may enhance the therapeutic efficacy of cisplatin by inhibiting the acquisition of chemoresistance by tumor and tumor-associated endothelial cells.
Several therapeutic approaches for targeting survivin protein using immunotherapy or small molecule antagonists either as single agents or in combination with conventional chemotherapeutic agents are currently in clinical trials (18) . Recently, a novel small molecule inhibitor of survivin, YM155, was identified by cell-based high-throughput screening (19) . It has been shown to exhibit potent anti-tumor activity in vitro, and induced tumor regression in established non-small cell lung cancer, non-Hodgkin's lymphoma, melanoma and hormone refractory prostate cancer xenografts (19) (20) (21) (22) . In addition, Phase I and Phase II trials with YM155 have demonstrated its safety and tolerability in patients with unresectable melanoma and advanced refractory NSCLC (23, 24) .
The objective of this study was to determine the in vitro and in vivo efficacy of YM155 alone or in combination with cisplatin in preclinical head and neck cancer models. YM155 treatment significantly down-regulated survivin expression in head and neck cancer cells, in a dose dependent manner, in vitro as well as in a preclinical in vivo model. In addition, YM155 treatment was able to reverse cisplatin resistance in a naturally occurring cisplatin resistant HNSCC cell line (UM-SCC-74A) as well as in a cisplatin resistant cell line (CAL27-CisR) with acquired cisplatin resistance. YM155 and cisplatin combination regimen was very well tolerated in vivo and significantly inhibited tumor growth and tumor angiogenesis. Taken together, our results demonstrate that YM155 could be a useful adjuvant for the treatment of head and neck cancer, particularly for the ones that are resistant to cisplatin and provides a scientific rationale to evaluate this or a similar combination strategy for clinical trials. Normal human oral keratinocytes (HOK) were purchased from ScienCell (Carlsbad, CA).
Human epidermal keratinocytes, adult (HEKa) and human epidermal keratinocytes, neonatal (HEKn) were purchased from (Invitrogen, Carlsbad, CA). All HNSCC cell lines were cultured in DMEM supplemented with 10% fetal bovine serum. HOK, HEKa and HEKn were grown in keratinocyte growth medium (Invitrogen). YM155 was obtained from Selleck Chemicals (Houston, TX). Cisplatin was purchased from Sigma-Aldrich (St. Louis, MO). Antibodies against survivin, ȕ-catenin, lamin A/C and GAPDH were obtained from Cell Signaling Technology (Danvers, MA). Survivin antibody for immunefluorescence was purchased from Novus Biologicals (Littleton, CO). CD31 antibody was from Dianova (Hamburg, Germany).
Induction of cisplatin resistance in a head and neck cancer cell line. CAL27 cells were initially cultured in DMEM containing 0.2ȝM cisplatin and the cells that proliferated were repeatedly sub-cultured in DMEM containing increasing concentrations of cisplatin over a 6 month period. Cells that grew in 20ȝM cisplatin were designated as CAL27-CisR. They were maintained in DMEM containing 3μM cisplatin.
Quantitative real time PCR analysis. RNA from the HNSCC tumors, adjacent normal controls, HNSCC cell lines was extracted using TRIZOL reagent (Invitrogen). RNA from paraffin embedded xenograft tumors was extracted using the RecoverAll mammalian RNA extraction kit (Ambion, Austin, TX). Survivin RNA was transcribed into cDNA and amplified with TaqMan primer/probe Hs03043576_m1. Survivin mRNA expression was normalized to RNU48 and OAZ1, respectively using the 2 -ǻǻCt method (27) .
Cell Proliferation Assay. Cell proliferation was measured using the MTT proliferation kit (Roche Applied Science, Mannheim, Germany) as described previously (28 Western blot analysis. Whole cell lysates or nuclear and cytoplasmic fractions were separated by 4-12% NuPAGE Bis-Tris gels (Invitrogen) as described previously (28) . Protein loading in all the experiments was normalized by stripping the blots and then re-probing with anti-GAPDH antibody.
Colony formation assay. Tumor cells were plated in 6 cm dishes and treated with cisplatin, YM155 or a combination of both. After 72 hours, 4x10 3 viable cells from each group were plated in 6 cm dishes and cultured for additional 10 days. The colonies were fixed with methanol and stained with crystal violet. Photomicrographs were taken and the number of colonies was counted by Alpha Innotech imaging software (San Leandro, CA).
Immunofluorescent staining. CAL27-CisR cells were cultured in 4-well labtech chambers.
CAL27-CisR cells were treated with YM155 (10 nM) for different time points. At the end of incubation, survivin localization was analyzed by immunofluorescent staining as described previously (29) . The fluorescent images were captured using Nikon Eclipse 80i microscope with DS-Ri1 camera at 600X magnification and overlaid using NIS-Elements-Basic Research software (Nikon, Melville, NY).
Matrigel in vitro endothelial tube formation assay. Endothelial tube formation was assayed using Matrigel coated 8-well chamber slides as described previously (30) . Each chamber was photographed (Nikon Eclipse Ti microscope with DS-Fi1 camera) at 100X magnification and total area occupied by endothelial cell derived tubes in each chamber was calculated using in patient samples from group 2, core samples were averaged across each patient to create one survivin stain intensity score. p16 staining was defined as positive if any core had a p16 stain proportion 50%. The smoking status group of 10 pack-years includes patients who reported pack-years of zero. Two-sample t tests were used in comparing mean survivin stain intensity between two independent groups. One-way ANOVA, or Kruskal-Wallis if assumptions were not met, were used to compare mean survivin stain intensity between three or more groups. If significant main effects were found, post hoc tests using a Bonferroni adjustment were performed. All statistical analyses for TMA data were conducted in SAS version 9. (Fig. 1A) . Analysis of group 2 patients showed that patients whose tumors were p16 negative had a significantly higher survivin stain intensity as compared to patients with p16 positive tumors (p<0.0001; Fig. 1B ). Similar results were obtained when HPV16 status was taken into consideration (p<0.021, Supplementary Table 2 ). Tumors from patients who smoked >10 pack-years had higher survivin stain intensity as compared to those with 10 pack-years smoking history (p<0.004, Fig. 1C ). In addition, patients with T4 stage tumors had significantly higher mean survivin stain intensity than those with T1 stage (p<0.01). We next examined if survivin expression is also elevated in head and neck tumor cell lines. Indeed, both survivin mRNA and protein levels were significantly higher in all the head and neck cancer cell lines as compared to normal keratinocytes (Mann-Whitney test; p=0.009 for RT-PCR data, Fig. 1D 
-E).
Survivin expression is markedly elevated in cisplatin resistant head and neck cancer cell line and treatment with YM155 significantly down-regulates survivin expression in a dosedependent manner. To examine the role of survivin in the acquisition of cisplatin resistance, we took a head and neck cancer cell line (CAL27) that is sensitive to cisplatin treatment (IC 50 3 μM) and induced cisplatin resistance by culturing this cell line in increasing doses of cisplatin over an extended period of time. This new cell line, designated CAL27-CisR (IC 50 28 μM) was found to be significantly more resistant to cisplatin treatment (> 7 folds) as compared to its parental cell line ( Fig. 2A) . Interestingly, CAL27-CisR cells also showed a significant increase in survivin levels as compared to CAL27 cells (Fig. 2B-C) . Survivin knockdown in CAL27-CisR cells significantly reversed cisplatin resistance in these cells (Fig. 2D-E) .
Recently, a novel small molecule inhibitor of survivin (YM155, Fig. 2G ) was identified by cell-based high-throughput screening (19) . We next examined if YM155 is effective in inhibiting survivin protein expression in head and neck cancer cell lines. We selected two cisplatin resistant cell lines UM-SCC-74A (naturally cisplatin resistant) and CAL27-CisR (generated in our laboratory) for our in vitro and in vivo work. YM155 significantly downregulated survivin expression in both the cell lines in a dose dependent manner (Fig. 2H-I ).
In addition, YM155 was very effective in inhibiting tumor cell proliferation (nano-molar concentrations) in HNSCC cell lines (Supplementary Fig. S1 ). For all the subsequent in vitro experiments using UM-SCC-74A and CAL27-CisR, we used the respective IC 50 doses of YM155 (15 and 10 nM for UM-SCC-74A and CAL27-CisR, respectively) and cisplatin (10 and 28 μM for UM-SCC-74A and CAL27-CisR, respectively) as a single agent or in combination.
YM155 significantly reverses cisplatin resistance in head and neck cancer cells by rapidly decreasing cytoplasmic survivin levels. Recent studies have highlighted the role of survivin in the acquisition of drug-resistance in cancer cells (12, 15, 16) . We next examined if YM155 could reverse the cisplatin resistance in head and neck cancer cells and enhance its anti-tumor effects.
Treatment of CAL27-CisR cells with cisplatin showed 51% inhibition of cell proliferation, whereas it completely inhibited cell proliferation in CAL27 cells (Fig. 3A) . Interestingly, pretreatment of CAL27-CisR cells with YM155 (10 nM) significantly reversed cisplatin resistance (90%) in CAL27-CisR cells (Fig. 3A) . Similarly, treatment with YM155 significantly reversed cisplatin resistance in naturally cisplatin resistant UM-SCC-74A cells ( Supplementary   Fig. S2 ). We next investigated the effect of YM155 alone or in combination with cisplatin on 
tumor cell colony formation. As observed with cell proliferation assay, YM155 and cisplatin combination treatment was very effective showing 96% inhibition of tumor cell colony formation, whereas YM155 and cisplatin alone showed 64% and 47% inhibition of tumor cell colony formation, respectively (Fig. 3C-D) . In the next set of experiments, we examined if YM155-induced inhibition of cell proliferation and colony formation is mediated via tumor cell apoptosis. Indeed, YM155 treatment in combination with cisplatin showed significantly higher tumor cell apoptosis (Fig. 3B) . In addition, YM155 and cisplatin combination treatment markedly reduced survivin levels in both UM-SCC-74A and CAL27-CisR cells (Fig. 3E-F) .
Recent studies have highlighted the role of cytoplasmic survivin in mediating the anti-apoptotic function (7) . We further performed immunofluorescence and sub-cellular fractionation studies to examine if YM155 treatment decreases cytoplasmic survivin levels in cancer cells. Our results clearly demonstrate that YM155 treatment rapidly decreases (within one hour) survivin levels in cytoplasmic cellular compartment, whereas nuclear survivin levels were not significantly decreased in the same cells (Fig. 3G-H and Supplementary Fig. S3 ).
Survivin has also been shown to regulate cell motility (34) . We next examined if YM155 treatment alone or in combination with cisplatin inhibits tumor cell motility. YM155 and cisplatin treatment alone showed 36% and 13% inhibition of CAL27-CisR cell motility and 39% and 14% inhibition of UM-SCC-74A cell motility respectively (Supplementary Fig. S4 ). YM155 and cisplatin combination treatment showed 74% and 70% inhibition of CAL27-CisR and UM-SCC-74A cell motility, respectively. mg/kg dose showed the maximal tumor growth inhibition (65% at day 36), whereas YM 155 at 3 mg/kg and 1 mg/kg showed 31% and 10% tumor growth inhibition, respectively, at day 36 ( Fig.   4A-B) . We next examined the effectiveness of different YM155 doses in downregulating survivin expression in vivo. Survivin expression in tumor samples at the end of the in vivo study (day 36) was examined by quantitative RT-PCR. Similar to tumor growth inhibition results, YM155 treatment at 1 mg/kg did not significantly decrease survivin levels. However, YM155 treatment at 3 mg/kg and 10 mg/kg doses significantly decreased survivin expression in UM-SCC-74A tumors (Fig. 4C ).
YM155 significantly enhances the therapeutic efficacy of cisplatin in cisplatin resistant
head and neck cancers. Our in vitro data suggest that YM155 significantly reverses cisplatin resistance in head and neck cancer cells. To further validate our in vitro results, we performed YM155 and cisplatin combination treatment study in a SCID mouse xenograft model. Animals bearing cisplatin resistant cells (CAL27-CisR) as well as its parental cisplatin sensitive cells (CAL27) showed a similar tumor growth profile (Fig. 5A-B) . As observed in our in vitro studies, cisplatin treatment (5 mg/kg) of animal bearing CAL27-CisR tumors did not significantly affect tumor growth (11% inhibition at day 36) whereas cisplatin treatment of CAL27 markedly decreased tumor growth (55% inhibition at day 36). YM155 (3 mg/kg) treatment of CAL27-CisR tumors was significantly more effective in reducing tumor burden (38% inhibition at day 36). YM155 in combination with cisplatin was most effective in inhibiting tumor growth of CAL27-CisR (66% inhibition at day 36).
We next tested the efficacy of YM155 and cisplatin combination treatment in a naturally cisplatin resistant head and neck cell line (UM-SCC-74A). Cisplatin (5 mg/kg) and YM155 (3 mg/kg) treatment alone showed 19% and 31% tumor growth inhibition (Fig. 5C-D YM155 and cisplatin in combination showed significantly higher tumor growth inhibition (64%).
In addition, the combination treatment was very well tolerated and it did not cause any animal mortality or induce significant decrease in body weight (Supplementary Fig. S5 ).
YM155 and cisplatin combination treatment significantly inhibits tumor angiogenesis. We have previously shown that VEGF, a key angiogenic factor, upregulated Bcl-2 proteins in endothelial cells via the PI3K/Akt pathway (35) and Bcl-2, in turn, protected endothelial cells by upregulating survivin via the Raf-MEK-ERK signaling cascade (36) . Recently, Virrey et al, have also shown that increased survivin expression confers chemoresistance to tumor-associated endothelial cells (37) . We therefore examined if YM155 treatment alone or in combination with cisplatin inhibits tumor angiogenesis. YM155 and cisplatin treatment alone showed 40% and 24% inhibition of tumor angiogenesis in UM-SCC-74A (Fig. 6A-B ) and 38% and 29% inhibition in CAL27-CisR, respectively (Fig. 6C) , whereas YM155 and cisplatin combination treatment showed 86% and 83% inhibition of tumor angiogenesis in UM-SCC-74A and CAL27-CisR tumors, respectively.
We next examined if YM155 combination treatment mediates its anti-angiogenesis effects by inhibiting VEGF-mediated angiogenesis. VEGF treatment of endothelial cells significantly enhanced the tube formation on growth factor reduced Matrigel (Fig. 6D-E) . Low dose combination of YM155 (10 nM) and cisplatin (5 μM) significantly inhibited (92%) VEGFmediated tube formation (Fig. 6D-E) , whereas YM155 and cisplatin treatment alone showed 45% and 34% inhibition of endothelial cell tube formation, respectively. VEGF treatment of endothelial cells markedly upregulated survivin levels, whereas YM155 treatment alone or in combination with cisplatin significantly inhibited survivin levels (Fig. 6F) . 
DISCUSSION
Head and neck squamous cell carcinoma (HNSCC) remains a challenging clinical problem due to the persistent high rate of local and distant failure which is in turn due to the acquisition of chemo and radio-resistance (38) . Therefore, there is an urgent need to identify new therapeutic targets so that novel treatment regimens can be developed to improve the therapeutic efficacy while minimizing the toxic side effects. One such target molecule for head and neck cancer is survivin protein. Recent studies have shown that survivin is largely undetectable in normal mucosa, but it is highly expressed in most head and neck cancers correlating with poor survival and resistance against chemotherapy and radiotherapy (10, 39, 40) . In our study, we also observed significantly higher levels of survivin in primary tumors from head and neck cancer patients as compared to surrounding normal tissue. In addition, survivin expression was also significantly upregulated in all head and neck cancer cell lines, both at the mRNA and protein 
and unable to tolerate the comorbidities normally associated with toxic chemotherapeutic agents.
Therefore, this non-HPV associated patient population could tremendously benefit from the addition of targeted therapies to currently used treatment regimens. In this study, we found that tumors from HPV negative patients express significantly higher levels of survivin as compared to tumors from HPV positive patients. We also found that survivin expression is higher in patients with a >10 pack-years of tobacco smoking history. This data gave us a strong rationale to test the anti-tumor effects of a novel survivin inhibitor YM155 in HNSCC. In this study, we have used 2 HPV negative HNSCC cell lines (UM-SCC-74A and CAL27-CisR). UM-SCC-74A cell line is derived from a head and neck cancer patient with base of tongue tumor and is highly resistant to both chemotherapy and radiation treatment (41, 42) . In addition, we generated a cisplatin resistant cell line (CAL27-CisR, IC 50 28 μM) in our laboratory by culturing a cisplatin sensitive tongue SCC cell line CAL27 (IC 50 3 μM) in increasing doses of cisplatin over a period of time.
YM155 treatment was very effective in inhibiting tumor cell proliferation in nano-molar concentrations in all HNSCC cell lines that we tested. In addition, YM155 pretreatment significantly reversed cisplatin resistance in a naturally resistant head and neck cell line (UM-SCC-74A) as well as in cell line with acquired cisplatin resistance (CAL27-CisR). YM155 treatment also significantly downregulated survivin expression in both of these cisplatin resistant cell lines in a dose dependent manner. Survivin has been shown to mediate its cytoprotective function predominantly at the initiation of mitochondrial apoptosis to prevent caspase-9 activation by forming a survivin-caspase-9 complex and preventing caspase-9 incorporation in a functional apoptosome complex (43, 44) . Interestingly, YM155 treatment induced a rapid reduction of cytoplasmic survivin levels in cancer cells. These results suggest that YM155 is not 
only able to downregulate survivin expression at the transcriptional level, but it may also be able to reduce cytoplasmic survivin levels by shuttling survivin from cytoplasm to nucleus and mediating its degradation (7, 45, 46) . This assumption is supported by recent studies demonstrating that only export competent survivin was able to efficiently inhibit chemo-and radiotherapy induced cell death (5, 47) . In line with this hypothesis, Engels et al showed that in patients with oral squamous cell carcinoma, increased cytoplasmic survivin levels were associated with significantly shorter disease free survival (8) . Therefore, these results highlight the importance of regulating not only the total levels, but also the localization of survivin in cancer cells. 
